ZIM Laboratories Limited

Drug companies are moving up the value chain, transforming into complex generic manufacturers with high end R&D facilities. Nagpur-based Zim Laboratories is a non-descript drug company with turnover in excess of Rs 250 crore. In the past two decades, Zim has been silently working on developing innovative and differentiated pharmaceutical products or specialty generic complex drugs. Recently, it developed a new product, Orally Disintegrating Strip (ODS) formulations up to 100 milligram, based on a patented oral thin film technology. These films, when placed on the tongue, adhere to the tongue mucosa and disintegrate almost instantaneously. There are only some 10 companies across the globe with this technology, but they are not able to grab a big share of the market due to prohibitive manufacturing costs. "With our technology, we can offer thin films at a price near to that of an oral tablet," says Anwar S. Daud, Managing Director of Zim Laboratories. Original Article ...

The Nagpur-based ZIM Laboratories, a leading provider of new drug delivery systems, has embarked on an initiative to expand its presence in Europe and US markets over the next three years with an investment of  Rs.  220 crore and broaden portfolio of novel and differentiated drug delivery solutions. Currently the firm is in talks with co-partners and distribution channels in Europe to start business activities by 2019 and will soon commence product registration there. Next step will be US market. For this, we are planning to set up a plant spanning over 6 acres of land in Multi-Modal International Air Cargo and Hub (MIHAN), Nagpur which we procured recently. The plant will develop products for US market after it is approved by US FDA. The products ranges from complex generics to drugs that went off patent over the last couple of years and drugs that will go off patent from 2018-2022, said Anwar S Daud, managing director of ZIM Labs. Original Article